Notable Representation:
Lead counsel for Genentech against Columbia University which had demanded that Genentech license a patent for a widely used recombinant DNA technique for producing protein in a host cell.
Genentech sued the University for obviousness-type double patenting.
Mr. Quinn’s team obtained the University’s agreement to a broad covenant not to sue Genentech for past, current or future infringement of the patent or any reissued patent with the same or similar claims.
@jbqlawFounder @quinnemanuel, largest biz litigation firm in the world. Contemporary art champion, and father of five.
The U.S. is using tariffs to push semiconductor manufacturing onto American soil. For Korea’s chip industry, the question is what happens next.
In my latest piece for the Korea Times @koreatimescokr, I look at what the current tariff negotiations mean for Samsung and SK hynix,
Continuation funds are either a way to hold on to an asset that still has room to grow, or a way to keep troubled assets on the books at stated valuations.
Either way, the conflicts are real and regulators are paying attention.
Read more: https://www.quinnemanuel.com/the-firm/publications/client-alert-continuation-funds-come-of-age-process-conflicts-and-the-first-wave-of-disputes/
I recently joined Rebecca Zung on Leverage to talk about what it takes to build the most feared litigation firm in the world. We also got into how AI is reshaping the profession and why most of Big Law is not ready for what is coming.
Watch the full conversation:
The biggest risk is often the one you don't see.
In my latest @Forbes Business Council article, I write about what entrepreneurs get wrong about risk and what the most resilient businesses do differently.
Read:
